StockNews.AI
IDBA
StockNews.AI
27 days

Mandatory disclosure of holding and notice of trade in IDEX Biometrics – 23 July 2025

1. IDEX Biometrics private placement of 9,090,909 shares at NOK 3.30 each. 2. CEO's company, Pinchcliffe AS, subscribed for 739,360 shares in Tranche 1. 3. Shares have been lent, not sold, maintaining major insider ownership. 4. Total insider ownership at 12.48% post-placement indicates confidence in IDEX. 5. IDEX specializes in biometric authentication solutions for payments and access.

4m saved
Insight
Article

FAQ

Why Neutral?

The private placement and insider share lending do not indicate immediate financial distress, as historical precedents show that insider investments can stabilize stock prices. However, the dilution of shares may not provide strong bullish sentiment in the short term.

How important is it?

The article's focus on insider transactions and share placements indicates investor sentiment, which can impact IDBA's trading behavior significantly, especially in the short term.

Why Short Term?

Initially, the private placement may lead to slight dilution concerns, but positive impacts from insider ownership may stabilize the price shortly after the announcement. In contrast, the long-term outlook will depend on future operational performance and market factors.

Related Companies

NOKIDEX
July 23, 2025 05:50 ET  | Source: IDEX BIOMETRICS ASA Reference is made to IDEX Biometrics ASA’s disclosure on 21 July 2025 of a private placement of 9,090,909 shares at NOK 3.30 per share. IDEX discloses the following information on behalf of a major shareholder and primary insider. Tranche 1 of the private placement amounted to 4,731,594 shares. As disclosed separately, Pinchcliffe AS, a company closely related to CEO and CFO Anders Storbråten, participated in the private placement and subscribed for 739,360 shares in Tranche 1. In connection with the private placement, the manager of the private placement, IDEX Biometrics and Mr. Storbråten entered into a share lending agreement. Mr. Storbråten has lent 4,731,594 shares, ISIN NO0013536078, in connection with the settlement of Tranche 1. The shares have been lent, not sold, and will be returned in due course.  After the subscription by Pinchcliffe and the temporary lending of shares, Mr. Storbråten and close relations hold 6,503,476 or 12,48% shares of the total outstanding shares and votes in IDEX Biometrics after completion of Tranche 1. Contact personAnders Storbråten, CEO and CFO Tel: +47 4163 8582E-mail: ir@idexbiometrics.com About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market. For more information, visit www.idexbiometrics.com About this noticeThis notice was issued by Erling Svela, Vice president of finance, on 23 July 2025 at 11:50 CET on behalf of IDEX Biometrics ASA. The information about the lending shall be disclosed according to article 19 no. 3 of the EU Market Abuse Regulation (EU 596/2014). The information about shareholding shall be disclosed according to section 4-2 of the Norwegian Securities Trading Act (STA). The information is published in accordance with section 5‑12 of the Norwegian Securities Trading Act.

Related News